Arcadia Biosciences (RKDA) Common Equity (2014 - 2025)

Arcadia Biosciences has reported Common Equity for 12 years, with the latest figure at $4.1 million in Q4 2025.

• For the quarter ending Q4 2025, Common Equity fell 33.47% year-over-year to $4.1 million; the trailing twelve-month figure through Dec 2025 stood at $4.1 million (down 33.47% YoY), and the FY2025 full-year result was $4.1 million, down 33.47% from the prior year.
• Common Equity for Q4 2025 stood at $4.1 million, down from $5.4 million in the prior quarter.
• The five-year high for Common Equity was $45.7 million in Q1 2021, with the low at $4.1 million in Q4 2025.
• Historically, Common Equity has averaged $19.3 million across 5 years, with a median of $16.0 million in 2023.
• Annual changes were most pronounced in 2021 — Common Equity jumped 273.91% — and 2025, when it plunged 60.81%.
• Arcadia Biosciences' Common Equity stood at $31.2 million in 2021, then slumped by 33.0% to $20.9 million in 2022, then plunged by 39.22% to $12.7 million in 2023, then slumped by 51.01% to $6.2 million in 2024, then plunged by 33.47% to $4.1 million in 2025.
• The last three Common Equity figures came in at $4.1 million (Q4 2025), $5.4 million (Q3 2025), and $4.5 million (Q2 2025), per Business Quant data.